Up-regulation of the phosphoinositide 3-kinase pathway in human lamina propria T lymphocytes

Human intestinal lamina propria T lymphocytes (LPT), when investigated ex vivo, exhibit functional properties profoundly different from those of peripheral blood T lymphocytes (PBT). One prominent feature represents their enhanced sensitivity to CD2 stimulation when compared to PBT. Given that LPT a...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental immunology Vol. 151; no. 3; pp. 496 - 504
Main Authors Braunstein, J, Autschbach, F, Giese, T, Lasitschka, F, Heidtmann, A, Sido, B, Funke, B, Reiser, C, Schröder, A.J, Nebl, G, Samstag, Y, Meuer, S.C
Format Journal Article
LanguageEnglish
Published Oxford, UK Oxford, UK : Blackwell Publishing Ltd 01.03.2008
Blackwell Publishing Ltd
Blackwell
Blackwell Science Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Human intestinal lamina propria T lymphocytes (LPT), when investigated ex vivo, exhibit functional properties profoundly different from those of peripheral blood T lymphocytes (PBT). One prominent feature represents their enhanced sensitivity to CD2 stimulation when compared to PBT. Given that LPT are hyporesponsive to T cell receptor (TCR)/CD3 stimulation, an alternative activation mode, as mimicked by CD2 triggering in vitro, may be functional in mucosal inflammation in vivo. This study provides insight into signalling events associated with the high CD2 responsiveness of LPT. When compared to PBT, LPT show an increased activation of the phosphoinositide 3/protein kinase B/glycogen synthase kinase 3β (PI3-kinase/AKT/GSK-3β) pathway in response to CD2 stimulation. Evidence is provided that up-regulation of this pathway contributes to the enhanced CD2-induced cytokine production in LPT. Given the importance of TCR-independent stimulation for the initiation of intestinal immune responses analysis of signalling pathways induced by 'co-stimulatory' receptors may provide valuable information for therapeutic drug design.
Bibliography:http://dx.doi.org/10.1111/j.1365-2249.2007.03562.x
Both authors contributed equally to this work.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Current address: Merck KGaA, Darmstadt
Current address: Roche Diagnostics GmbH, Mannheim, Germany
ISSN:0009-9104
1365-2249
DOI:10.1111/j.1365-2249.2007.03562.x